ArticleEuropean journal of nuclear medicine and molecular imaging2009
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
Article in European journal of nuclear medicine and molecular imaging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Meta-analysis of [European radiology · 2025Pooled it
- [Diagnosis and treatment of sarcoidosis. Current standards].Der Internist · 2015Guideline
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- ACE and chitotriosidase as possible predictive biomarkers for activity of sarcoidosis in correlation with PET/CT findings.Journal of medical biochemistry · 2025Article
- Parathyroid-independent hypercalcemia as initial presentation of renal sarcoidosis with granulomatous interstitial nephritis: a case report.Frontiers in endocrinology · 2025Review
- Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosisSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- 2-deoxy-2[18F]fluoro-D-glucose positron emission tomography-computed tomography in rheumatological diseases.Rheumatology (Oxford, England) · 2022Review
- FeV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients.BMC pulmonary medicine · 2021Article
- In Which Patients with Sarcoidosis Is FDG PET/CT Indicated?Journal of clinical medicine · 2020Review
- Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).American heart journal · 2020Article
- Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.Frontiers in immunology · 2020Review
- Quantification of pulmonary disease activity in sarcoidosis measured withEJNMMI research · 2019Article
- YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.Biomolecules · 2018Article
- Volumetric FDG PET analysis of global lung inflammation: new tool for precision medicine in pulmonary sarcoidosis?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Biological role of the soluble interleukin-2 receptor in sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2017Article
- PET/CT in nononcological lung diseases: current applications and future perspectives.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- Positron emission tomography imaging in sarcoidosis.World journal of nuclear medicine · 2013Review
- A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.BMC pulmonary medicine · 2012Article
- [Bilateral recurrent blurred vision associated with halos around sources of light and headache].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2012Article
- Clinical use of biomarkers of survival in pulmonary fibrosis.Respiratory research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAngiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R) are serological markers, widely used for determining sarcoidosis activity. (18)F-FDG PET has proven to be a sensitive technique in the imaging of sarcoidosis. The aim of this study was to determine sensitivity of (18)F-FDG PET, genotype-corrected ACE and sIL-2R in active sarcoidosis as well as their correlation.
methodsThis retrospective study included 36 newly diagnosed, symptomatic sarcoidosis patients. ACE and sIL-2R levels were simultaneously obtained within 4 weeks of (18)F-FDG PET. ACE was corrected for genotype and expressed as Z-score. (18)F-FDG PET was visually evaluated and scored as positive or negative. Maximum and average standardized uptake values (SUV(max) and SUV(avg)) were compared with ACE and sIL-2R.
results(18)F-FDG PET was found positive in 34 of 36 patients (94%). Thirteen patients (36%) showed an increased ACE with the highest sensitivity found in patients with the I/I genotype (67%). Seventeen patients (47%) showed an increased sIL-2R. No correlation was found between SUV and ACE or sIL-2R. Increased ACE and sIL-2R correlated with a positive (18)F-FDG PET in 12 patients (92%) and 16 patients (94%), respectively.
conclusion(18)F-FDG PET is a very sensitive technique to assess active sarcoidosis, in contrast with ACE and sIL-2R, suggesting a pivotal role for (18)F-FDG PET in future sarcoidosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.